Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

Executive Summary

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

You may also be interested in...



iTeos Says Adios To IDO And Eyes US IPO

An oversubscribed financing round led by new US investor MPM Capital has brought in $75m for the Belgian company. Much of it will be used to advance its potential best-in-class adenosine A2A receptor now that its IDO1 drug has been shelved.

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug

Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel